Moreover, an in vivo study by Schnoder et al. (2016) showed that a low level of MAPK14 facilitates the lysosomal degradation of BACE1, resulting in the attenuation of amyloid pathology in AD. This evidence concerns the gene MAPK14 and Alzheimer disease.